Clariant FY Sales From Cont. Ops. Down 5 %

Clariant AG (CLZNY.PK,CRN.L,CLZNF.PK) reported a 5% decline in sales from continuing operations for fiscal 2020.

For the full year 2020, continuing operations sales totaled CHF 3.860 billion, compared to CHF 4.399 billion in 2019. This corresponds to a decrease of 5 % in local currency and 12 % in Swiss francs due to depreciating currencies versus the Swiss franc. Pricing had a positive impact on the Group, the company said.

In 2020, the net result for the total Group increased to CHF 799 million from CHF 38 million in the previous year.

In the fourth quarter of 2020, sales from continuing operations declined by 2 % in local currency and by 9 % in Swiss francs to CHF 1.022 billion.

Looking forward, Clariant expects that the COVID-19 pandemic will still negatively impact sales, especially in Natural Resources, in the first quarter of 2021 versus the pre-COVID-19 comparable base in the first quarter of 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT